BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model.

J Allergy Clin Immunol. 1998 Nov;102(5):867-74. Unique Identifier : AIDSLINE MED/99036725
Herz U; Gerhold K; Gruber C; Braun A; Wahn U; Renz H; Paul K; Departments of Laboratory Medicine and Pathobiochemistry and; Pediatric Pulmonology and Immunology, Charite, Campus; Virchow-Clinic, Berlin, Germany.

Abstract: BACKGROUND: Epidemiologic studies suggest an inverse correlation between infections and development of atopy. The purpose of this study was to test the hypothesis whether a preexisting Th1-type immune response elicited by BCG immunization could suppress allergic sensitization and airway hyperreactivity in an animal model. METHODS: BALB/c mice were immunized with BCG and/or sensitized to ovalbumin. RESULTS: BCG immunization alone resulted in cutaneous type-IV hypersensitivity reactions to tuberculin and granulomatous lesions in the liver. Splenic mononuclear cells (MNCs) produced increased levels of IFN-gamma after activation by Concanavalin A (ConA). Ovalbumin sensitization alone resulted in increased production of IL-4 after activation by ConA. Ovalbumin-sensitized animals also demonstrated markedly elevated anti-ovalbumin IgE/IgG1 serum antibody titers and increased airway reactivity after allergen challenges by means of the airways. BCG immunization 14 days before the start of ovalbumin sensitization markedly hindered the development of allergic responses as indicated by (1) increased IFN-gamma and normalized IL-4 and IL-10 production by splenic MNCs after activation with ConA, (2) a reduced proliferation rate of splenic MNCs after ovalbumin restimulation, (3) partial prevention of ovalbumin-specific IgE/IgG1 serum antibody titers but elevated (nonallergic) anti-ovalbumin IgG2a serum antibody titers, (4) prevention of airway responsiveness, (5) reduced eosinophilic influx into the airway lumen, and (6) reduced levels of IL-4 and IL-5 in broncho alveolar lavage fluids. CONCLUSION: In this model BCG immunization established a Th1-type immune response that hinders allergic sensitization and the development of increased airway reactivity.
Keywords: JOURNAL ARTICLE Animal Asthma/*IMMUNOLOGY/PREVENTION & CONTROL/PHYSIOPATHOLOGY Bronchial Hyperreactivity/PREVENTION & CONTROL Bronchoalveolar Lavage Fluid/CHEMISTRY BCG Vaccine/*IMMUNOLOGY Disease Models, Animal Female Hypersensitivity, Delayed/IMMUNOLOGY Immunization Interleukin-4/METABOLISM Interleukin-5/METABOLISM Mice Mice, Inbred BALB C Ovalbumin/IMMUNOLOGY Support, Non-U.S. Gov't Th1 Cells/PHYSIOLOGYKWDjournalarticleanimalasthma/KWDimmunology/prevention&control/physiopathologybronchialhyperreactivity/prevention&controlbronchoalveolarlavagefluid/chemistrybcgvaccine/KWDimmunologydiseasemodels,animalfemalehypersensitivity,delayed/immunologyimmunizationinterleukin-4/metabolisminterleukin-5/metabolismmicemice,inbredbalbcovalbumin/immunologysupport,non-uKWDsKWDgov'tth1cells/physiology
990228
A9920499

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .